JaLCDOI 10.18926/AMO/30986
フルテキストURL fulltext.pdf
著者 Ebara, Shin| Katayama, Yoshihisa| Tanimoto, Ryuta| Edamura, Kohei| Nose, Hiroyuki| Manabe, Daisuke| Kobayashi, Tomoko| Kobayashi, Yasuyuki| Kobuke, Makoto| Takemoto, Mitsuhiro| Saika, Takeshi| Nasu, Yasutomo| Kanazawa, Susumu| Kumon, Hiromi|
抄録 <p>From January 2004 to March 2007, 308 patients with clinically localized prostate cancer were treated using iodine-125 (125I) seed implantation (permanent brachytherapy) at Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences. We evaluated the treatment’s effi cacy and morbidity in 300 prostate cancer patients who were followed up for more than 1 month after brachytherapy. Based on the National Comprehensive Cancer Network (NCCN) guidelines, patients with a prostate volume of less than 40 ml in transrectal ultrasound imaging were classifi ed as low or intermediate risk. The median patient age was 67 years (range 50 to 79 years), the median prostate-specific antigen (PSA) value before biopsy was 6.95 ng/ml (range 1.13 to 24.7 ng/ml), and the median prostate volume was 24.33 ml (range 9.3 to 41.76 ml). The median follow-up was 18 months (range 1 to 36 months) and the PSA levels decreased in almost all patients after brachytherapy. Although 194 of 300 patients (64.7%) complained of diffi culty in urination, pollakisuria/urgency, miction pain, and/or urinary incontinence, all of which might be associated with radiation prostatitis during the fi rst month after brachytherapy, these symptoms gradually improved. 125I seed implantation brachytherapy is safe and eff ective for localized prostate cancer within short-term follow up.</p>
キーワード localized prostate cancer brachytherapy prostate specific antigen urinary morbidity
Amo Type Original Article
発行日 2008-02
出版物タイトル Acta Medica Okayama
62巻
1号
出版者 Okayama University Medical School
開始ページ 9
終了ページ 13
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
論文のバージョン publisher
査読 有り
PubMed ID 3558
Web of Sience KeyUT 000255297600011